Review
The Journal of the Korean Rheumatism Association 2006; 13(1): 1-9
Published online March 30, 2006
© Korean College of Rheumatology
강직성척추염의 치료
허민영·신동혁*·김태환
한양대학교 류마티스병원, 을지의과대학교 내과*
The conventional approach to treatment of patients with ankylosing spondylitis (AS) have been rather limited in the last decades. Evidence is accumulating that tumor necrosis factor (TNF) blocker is highly effective in AS. This article reviews the most recent and the most pertinent advances in the treatment in AS. TNF blocker have been evaluated in a number of randomized controlled trials in AS and have been demonstrated to be effective in disease activity, function, and quality of life in these patients. TNF blocker is emerging as the best therapeutic option available for patients with AS.
Keywords Ankylosing spodylitis, Treatment, Tumor necrosis factor blocker
PDF
Standard view
Export citation
Share Article
Review
The Journal of the Korean Rheumatism Association 2006; 13(1): 1-9
Published online March 30, 2006
Copyright © Korean College of Rheumatology.
강직성척추염의 치료
허민영·신동혁*·김태환
한양대학교 류마티스병원, 을지의과대학교 내과*
Treatment of Ankylosing Spondylitis
Min-Young Her, M.D., Donghyuk Sheen, M.D.*, Tae-Hwan Kim, M.D.
Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Diseases, Hanyang University College of Medicine, Seoul, Internal Medicine, Eulji University School of Medicine, Daejeon*, Korea
Correspondence to:Tae-Hwan Kim
Abstract
The conventional approach to treatment of patients with ankylosing spondylitis (AS) have been rather limited in the last decades. Evidence is accumulating that tumor necrosis factor (TNF) blocker is highly effective in AS. This article reviews the most recent and the most pertinent advances in the treatment in AS. TNF blocker have been evaluated in a number of randomized controlled trials in AS and have been demonstrated to be effective in disease activity, function, and quality of life in these patients. TNF blocker is emerging as the best therapeutic option available for patients with AS.
Keywords: Ankylosing spodylitis, Treatment, Tumor necrosis factor blocker
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung Seo, M.D., Jina Yeo, M.D., Jun Won Park, M.D., Yeon-Ah Lee, M.D., Ph.D., Ju Ho Lee, M.D., Eun Ha Kang, M.D., Ph.D., Seon Mi Ji, M.D., Ph.D., Seong-Ryul Kwon, M.D., Ph.D., Seong-Kyu Kim, M.D., Ph.D., Tae-Jong Kim, M.D., Ph.D., Tae-Hwan Kim, M.D., Ph.D., Hye Won Kim, M.D., Ph.D., Min-Chan Park, M.D., Ph.D., Kichul Shin, M.D., Ph.D., Sang-Hoon Lee, M.D., Ph.D., Eun Young Lee, M.D., Ph.D., Hoon Suk Cha, M.D., Ph.D., Seung Cheol Shim, M.D., Ph.D., Youngim Yoon, RN, Seung Ho Lee, Jun Hong Lim, Han Joo Baek, M.D., Ph.D.; on behalf of the Korean Society of Spondyloarthritis Research
J Rheum Dis 2023; 30(3): 151-169 -
Korean guidelines for the management of gout
Jennifer Jooha Lee, M.D., Ph.D., Ji Soo Lee, M.D., Ph.D., Min Kyung Chung, M.D., Ph.D., Joong Kyong Ahn, M.D., Ph.D., Hyo-Jin Choi, M.D., Ph.D., Seung-Jae Hong, M.D., Ph.D., Chong-Hyeon Yoon, M.D., Ph.D., Su-Hyun Kim, M.D., Ph.D., Kyung-Hwan Jeong, M.D., Ph.D., Jong-Woo Kim, M.D., Bo-Yeon Kim, M.D., Ph.D., Jin-Ho Shin, M.D., Ph.D., Woo Gyu Kim, M.D., Soo-Young Kim, M.D., Ph.D., Hyun-Jung Kim, Ph.D., Jeong-Soo Song, M.D., Ph.D., Jae-Bum Jun, M.D., Ph.D., Hyun-Ah Park, M.D., Ph.D., Shung Chull Chae, M.D., Ph.D., Bum Soon Choi, M.D., Ph.D., Tae Nyun Kim, M.D., Ph.D., Hyun Ah Kim, M.D., Ph.D.
J Rheum Dis 2023; 30(3): 141-150 -
Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean
Joong Kyong Ahn, M.D., Ph.D.
J Rheum Dis 2023; 30(2): 88-98
